AbstractBackgroundα1-antagonists are commonly used to treat benign prostatic hyperplasia. Preclinical studies suggest they induce cell death and inhibit tumor growth. This study evaluates the risk of prostate cancer death in men using α1-antagonists.MethodsA population-based cohort study in Stockholm, Sweden (January 1, 2007 to December 31, 2019) including...

AbstractBackgroundAlthough breast cancer survivors are at risk for cardiovascular disease (CVD) from treatment late effects, evidence to inform long-term and age-specific cardiovascular surveillance recommendations is lacking.MethodsWe conducted a retrospective cohort study of 10,211 women diagnosed with first primary unilateral breast cancer in Kaiser...

AbstractBackgroundAnal cancer risk is elevated among people with HIV (PWH). Recent anal cancer incidence patterns among PWH in the United States (US) and Canada remain unclear. It is unknown how the incidence patterns may evolve in future years.MethodsUsing data from the North American AIDS Cohort Collaboration on Research and Design, we investigated...

AbstractBackgroundCamonsertib is a selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with demonstrated efficacy in tumors with DNA damage response gene deficiencies. On-target anemia is the main drug-related toxicity typically manifesting after the period of dose-limiting toxicity evaluation. Thus dose/schedule optimization...